8月7日 - ** 药物开发商Replimune（REPL.O）的股价在盘前交易中下跌5%，至12.21美元
** 周四晚间，美国食品药品监督管理局（FDA）授予Replimune公司旗下药物Tudriqev加速批准 (link)，该药适用于此前经治疗后肿瘤仍继续生长的晚期黑色素瘤患者
** 韦德布什（Wedbush）分析师罗伯特·德里斯科尔（Robert Driscoll）表示，该股走弱可能与FDA批准的说明书有关，其中提及的客观缓解率（ORR）为24%，低于此前强调的33%这一数据
** 客观缓解率（ORR）衡量的是治疗后肿瘤缩小或消失的患者所占的比例
** 德里斯科尔指出，较低的客观缓解率反映了至少有一个未接受注射治疗的目标病灶的患者数据
** Replimune在电话会议上向投资者表示，预计说明书措辞不会影响该疗法的采用
** 该公司表示，Tudriqev的平均疗程费用约为45万美元，预计将在大约60天后开始发货
** 截至上一交易日收盘，该股年内累计上涨32.3%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.